BioCentury | Mar 5, 2012
Clinical News

SCV-07: Development discontinued

...oncology indications in the future. SciClone has exclusive rights to SCV-07 outside of Russia from Verta...
...commercial business in China. Details were not disclosed. SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Verta Ltd....
BioCentury | Mar 3, 2012
Clinical News

SciClone discontinues oral mucositis therapy

...cancer indications in the future. SciClone has exclusive rights to SCV-07 outside of Russia from Verta Ltd....
BioCentury | Jun 13, 2011
Clinical News

SciClone, Verta preclinical data

...rights to SCV-07 outside of Russia from Verta. SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Verta Ltd....
BioCentury | Jan 17, 2011
Clinical News

SCV-07: Phase IIb started

...rights to SCV-07 outside of Russia from Verta. SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Verta Ltd....
BioCentury | Dec 20, 2010
Clinical News

SCV-07: Phase IIb data

...the indication early next year. SciClone has exclusive rights to SCV-07 outside of Russia from Verta...
...SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Pegasys and Copegus. SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Verta Ltd....
BioCentury | Dec 16, 2010
Clinical News

SciClone discontinues SCV-07 for HCV

...the indication early next year. SciClone has exclusive rights to SCV-07 outside of Russia from Verta Ltd....
BioCentury | Oct 11, 2010
Clinical News

SCV-07: Additional Phase IIa data

...rights to SCV-07 outside of Russia from Verta. SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Verta Ltd....
BioCentury | Apr 5, 2010
Clinical News

SCV-07: Phase II data

...exclusive rights to SCV-07 outside Russia from Verta. SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Verta Ltd....
BioCentury | Dec 7, 2009
Clinical News

SCV-07: Completed Phase II enrollment

...exclusive rights to SCV-07 outside Russia from Verta. SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Verta Ltd....
BioCentury | Nov 2, 2009
Clinical News

SCV-07: Phase II started

...exclusive rights to SCV-07 outside Russia from Verta. SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Verta Ltd....
Items per page:
1 - 10 of 17
BioCentury | Mar 5, 2012
Clinical News

SCV-07: Development discontinued

...oncology indications in the future. SciClone has exclusive rights to SCV-07 outside of Russia from Verta...
...commercial business in China. Details were not disclosed. SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Verta Ltd....
BioCentury | Mar 3, 2012
Clinical News

SciClone discontinues oral mucositis therapy

...cancer indications in the future. SciClone has exclusive rights to SCV-07 outside of Russia from Verta Ltd....
BioCentury | Jun 13, 2011
Clinical News

SciClone, Verta preclinical data

...rights to SCV-07 outside of Russia from Verta. SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Verta Ltd....
BioCentury | Jan 17, 2011
Clinical News

SCV-07: Phase IIb started

...rights to SCV-07 outside of Russia from Verta. SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Verta Ltd....
BioCentury | Dec 20, 2010
Clinical News

SCV-07: Phase IIb data

...the indication early next year. SciClone has exclusive rights to SCV-07 outside of Russia from Verta...
...SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Pegasys and Copegus. SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Verta Ltd....
BioCentury | Dec 16, 2010
Clinical News

SciClone discontinues SCV-07 for HCV

...the indication early next year. SciClone has exclusive rights to SCV-07 outside of Russia from Verta Ltd....
BioCentury | Oct 11, 2010
Clinical News

SCV-07: Additional Phase IIa data

...rights to SCV-07 outside of Russia from Verta. SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Verta Ltd....
BioCentury | Apr 5, 2010
Clinical News

SCV-07: Phase II data

...exclusive rights to SCV-07 outside Russia from Verta. SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Verta Ltd....
BioCentury | Dec 7, 2009
Clinical News

SCV-07: Completed Phase II enrollment

...exclusive rights to SCV-07 outside Russia from Verta. SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Verta Ltd....
BioCentury | Nov 2, 2009
Clinical News

SCV-07: Phase II started

...exclusive rights to SCV-07 outside Russia from Verta. SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Verta Ltd....
Items per page:
1 - 10 of 17